IBRXImmunityBio Inc
IBRX
ImmunityBio Inc28,549
Mkt Cap
$7.48BVolume
14.36M52W High
$12.4352W Low
$1.83PE Ratio
-18.68IBRX Fundamentals
Price
$7.28Prev Close
$7.48Open
$7.3550D MA
$7.83Beta
1.96Avg. Volume
27.67MEPS (Annual)
-$0.382P/B
-14.72Rev/Employee
$163,947.90$2,424.07
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit...
PR Newswire·11h ago
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC ImmunityBio, Inc. Securities Fraud Class...
PR Newswire·1d ago
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.
Zacks·2d ago
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the...
Business Wire·2d ago
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio...
PR Newswire·2d ago
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman ImmunityBio, Inc...
PR Newswire·3d ago
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP PR Newswire...
PR Newswire·3d ago
ImmunityBio (NASDAQ:IBRX) Trading Up 7.1% - Still a Buy?
ImmunityBio (NASDAQ:IBRX) Trading Up 7.1% - Here's What Happened...
MarketBeat·3d ago
Why Is ImmunityBio Stock Rallying Thursday?
ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning prompts review of promotional claims.read more...
Benzinga·3d ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX INVESTOR ALERT: Pomerantz Law Firm...
PR Newswire·3d ago
<
1
2
...
>